Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 37%?

3d ago, source:

Current share price of US$58.61 suggests Keros Therapeutics is potentially 37% undervalued The US$88.11 analyst price target for KROS is 5.7% less than our estimate of fair value ...

Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

1mon ago, source: Hosted on MSN

Keros Therapeutics, Inc. (KROS) is one of the several suitable candidates that passed through the screen. Here are the key reasons why it could be a profitable bet for "trend" investors.

Keros Therapeutics Inc KROS

2d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

1mon ago, source: Business Insider

LEXINGTON, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...

Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference

1mon ago, source: Stockhouse

LEXINGTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment

1mon ago, source: Business Insider

Analyst Thomas Smith of Leerink Partners maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price target of $85.00. Thomas Smith has given his Buy rating due to a ...

Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

1mon ago, source: Finanznachrichten

Keros Therapeutics Inc reports results for the quarter ended in December - Earnings Summary 28.02. Keros Therapeutics GAAP EPS of -$1.34 beats by $0.04, revenue of $0.14M ...

Keros Therapeutics Inc KROS

24d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics Inc.

21d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...